The clinical utility of minimal residual disease (MRD) measurements following allogeneic stem cell transplantation (SCT) in childhood ALL is controversial. We therefore performed a multi-institutional study of MRD in bone marrow samples taken before SCT and at 1, 3, 6 and 12 months after SCT. Case-specific clonal rearrangements of IgH and TCR genes and expression levels of Wilms' tumor 1 (WT1) mRNA were determined by PCR or RT-PCR methods. In total, 95 cases met all criteria for analysis of informative IgH/TCR markers and quantitative WT1 mRNA expression levels. During the 2-year (median 414 days) study period, 20 patients relapsed. Although the proportion of patients with a positive IgH/ TCR result before SCT was significantly reduced at 1 month after treatment (Po0.001), attesting the efficacy of SCT, serial measurements of IgH/TCR rearrangements did not correlate with leukemic relapse. Clonal switch was demonstrated in 11 of the 14 patients with bone marrow relapse, indicating that the poor predictive power of the MRD assay most likely reflected the loss of PCR targets. WT1 expression was not related to either MRD detection by IgH/TCR assays or to clinical leukemic relapse. The clinical value of serial MRD monitoring would be limited in ALL patients undergoing SCT.
Summary:
The clinical utility of minimal residual disease (MRD) measurements following allogeneic stem cell transplantation (SCT) in childhood ALL is controversial. We therefore performed a multi-institutional study of MRD in bone marrow samples taken before SCT and at 1, 3, 6 and 12 months after SCT. Case-specific clonal rearrangements of IgH and TCR genes and expression levels of Wilms' tumor 1 (WT1) mRNA were determined by PCR or RT-PCR methods. In total, 95 cases met all criteria for analysis of informative IgH/TCR markers and quantitative WT1 mRNA expression levels. During the 2-year (median 414 days) study period, 20 patients relapsed. Although the proportion of patients with a positive IgH/ TCR result before SCT was significantly reduced at 1 month after treatment (Po0.001), attesting the efficacy of SCT, serial measurements of IgH/TCR rearrangements did not correlate with leukemic relapse. Clonal switch was demonstrated in 11 of the 14 patients with bone marrow relapse, indicating that the poor predictive power of the MRD assay most likely reflected the loss of PCR targets. WT1 expression was not related to either MRD detection by IgH/TCR assays or to clinical leukemic relapse. The clinical value of serial MRD monitoring would be limited in ALL patients undergoing SCT. Bone Marrow Transplantation (2003) 31, 1127-1135. doi:10.1038/sj.bmt.1704067
Keywords: minimal residual disease; childhood acute lymphocytic leukemia; Wilms tumor gene 1 (WT1); allogeneic stem cell transplantation Minimal residual disease (MRD) detection has been used extensively to predict treatment outcome in childhood leukemia. [1] [2] [3] [4] [5] [6] [7] [8] Currently, either one or two combinations of sensitive procedures are used to detect MRD. These include quantitative flow cytometry 6, 8, 9, 10 and PCR/RT-PCR analysis for patient-specific IgH or T-cell receptor (TCR) genes. 7, 11 Leukemia-specific chimeric genes, 12, 13 the chimeric status of bone marrow transplant (BMT) recipients, 14, 15 and Wilms tumor gene 1 (WT1) mRNA expression 16 are also employed. The general intent of these procedures is to guide therapeutic decisions regarding patients on risk-adjusted treatment protocols. Recent studies have indicated that a high level of MRD at the end of induction chemotherapy predicts marrow relapse of ALL. 2, 4 Indeed, findings in two large series of childhood ALL patients strongly suggested that MRD is one of the most important predictors of outcome once treatment has commenced. 2, 4 On the other hand, the usefulness of MRD detection in patients undergoing hematopoietic stem cell transplantation (SCT) remains controversial. MRD assays have been used successfully to evaluate the quality of autologous peripheral blood stem cells (PBSCs) or BMTs. 1 In other studies, Knechtli et al. 17, 18 demonstrated a good correlation of pre-BMT MRD levels with 2-year event-free survival rates, and of post-BMT MRD positivity with subsequent relapse, using PCR to detect Ig or TCR-g, -d rearrangements. Thus, in principle, MRD monitoring may be a useful means of assessing the efficacy of SCT and of identifying patients who might benefit from experimental therapy.
The WT1 gene is a unique panleukemia marker of MRD. 16, [19] [20] [21] [22] Using an assay based on WT1 mRNA expression levels, Sugiyama and co-workers [19] [20] [21] reported that molecular relapse could be diagnosed before it became clinically apparent. This group found that the WT1 gene was expressed in 73-100% of patients with acute myeloid leukemia (AML) and in as many as 60% of patients with ALL. To establish the utility of MRD monitoring after SCT in children with ALL, we employed multiple residual disease markers. These included patient-specific IgH and TCR gene rearrangements, and the expression of chimeric minor bcr-abl and WT1 mRNA transcripts.
Patients, materials and methods

Patients
Any child (age o20 years) with ALL who underwent allogeneic SCT at 1 of the 50 participating Japanese centers (see Appendix) between June 1998 and September 2000 was a candidate for study. Of the 112 patients entered the study, seven patients died of transplant-related morbidity were excluded. Thus, a total of 95 patients (54 boys and 41 girls with median ages of 9 years, respectively) met the eligibility criteria of more than three bone marrow samples for analysis (one active disease at diagnosis or relapse pre-SCT and multiple points post-SCT). This cohort comprised 84 B-lineage and 11 T-lineage cases. In total, 10 cases were positive for the Philadelphia chromosome. The status of leukemia at the time of transplant was as follows: complete remission 68 cases (CR1 ¼ 25, CR2 ¼ 36, CR3 ¼ 6, CR4 ¼ 1) and active disease 27 cases (induction failure ¼ 3, 3, relapse ¼ 24). We defined risk groups as very high risk (n ¼ 32) for the cases of Philadelphia chromosome-positive and/or active disease at transplantation, while the remaining cases were high risk. The source of stem cells for allogeneic transplantation was bone marrow in 60 cases and cord blood in 22. The conditioning regimens included total-body irradiation (TBI) in 72 cases, and intensive chemotherapy only in 23 cases. A total of 95 patients had bone marrow samples that were successfully prepared for detection of patient-specific IgH/TCR rearrangements. All 10 cases of Philadelphia chromosome-positive leukemia expressed the minor bcr-abl fusion gene. WT1 expression levels were determined at pre-and post-SCT in 74 cases. Enrollment in the study was contingent upon the informed consent of the patients or their guardians (Table 1) .
Sample correction and preparation
Bone marrow cells collected at diagnosis, before and at 1, 3, 6 and 12 months after SCT and at relapse were shipped to central laboratories (the Mitsubishi Laboratory for PCR analysis of IgH/TCR rearrangements, and the Otsuka Laboratory for RT-PCR analysis of WT1 and minor bcrabl mRNAs). Mononuclear cells were isolated from bone marrow by density centrifugation, and their RNA extracted by Trizol (Gibco BRL, Paisley, UK). The quality of RNA was checked by the amount of b-actin (10 6 copies/mg RNA). The remaining samples were stored in liquid nitrogen for later DNA extraction with DnaQuick DNA extraction kit (Dainippon Pharmaceutical Co., Osaka, Japan).
MRD detection
PCR and RT-PCR analyses were performed according to standard procedures. 23, 24 For the detection of IgH/TCR MRD, genomic DNA was amplified by PCR method. The PCR products were fractionated by gel electrophoresis on 3% agarose gel (Agarose ME, Iwai Chemical, Tokyo, Japan) and stained with ethidium bromide (Roche diagnostics). After Southern blotting, the DNA was hybridized with clone-specific oligonucleotide probe that was endlabeled using [g-32 P ¼ ATP and T4 polynucleotide kinase (TaKaRa BIOMEDICALS, Kyoto, Japan). After washing of the membrane, it was exposed to X-ray film (HR-HA30, Fuji photo film, Tokyo, Japan) for overnight at À801C. The autoradiogram was used for an analysis. Sequencing was carried out with the ABI PRIZMt 377 DNA Sequencing System (PE Biosystems). Informative clonal rearrangements of IgH and TCR genes detected by PCR were as follows: for IgH(n ¼ 84), clonal VH-JH (two-step PCR with sense; FR3A, antisense; LJH/VLJH), for TCRg(n ¼ 4), Vg-Jg (sense; five sets of V-region primers, antisense; three sets of J-region primers) and for TCRd(n ¼ 7), nested PCR detecting each VDJd1-TCR recombination, Vd2-Dd3 recombination and Vd2-Dd3-Ja. A qualitative RT-PCR method was used to detect the minor bcr-abl mRNA, while WT1 mRNA expression was assayed by a competitive RT-PCR method using the following primers, WT1-RT (5
Values were expressed as WT1 copy/mg RNA and tentatively classified as low (o1.0 Â 10 4 of total extracted bone marrow mononuclear cells, respectively. Although MRD assays were performed for only up to 12 months, all transplant recipients were clinically followed until 24 months to document later ALL relapses. Clonal evolution was assessed in 14 cases of hematologic relapse by performing PCR with the primer sets used in the original IgH or TCR analysis and by comparing the sequences of PCR products in diagnostic vs relapse samples.
Data analysis
The principal end points of the study were (i) the initial efficacy of SCT based on MRD detection, (ii) the correlation between serial monitoring of MRD and post-SCT relapse, (iii) the correlation of WT1 mRNA expression levels with qualitative PCR detection of IgH/TCR rearrangements and (iv) risk factors related to SCT efficacy. Since 68 patients were transplanted in CR while 27 on disease, the efficacy of SCT on MRD and relapse was also compared between these two groups. Relapse-free survival (RFS) was estimated by the Kaplan-Meier method. Survival distributions were compared with the log-rank test, while Fisher's exact test or a paired t-test was applied in comparisons of categorical data.
Results
Efficacy of SCT based on initial MRD measurements
Before SCT, 88 (95.7%) of 92 bone marrow samples were positive for IgH/TCR rearrangements, while at 1 month post-SCT, this proportion was significantly reduced to 16 
Correlation of IgH/TCR positivity with expression of WT1 and minor bcr-abl RNAs
Since the levels of WT1 expression were quite variable from case to case, they were classified as low (o1.0 Â 10 . At various times after SCT, the distribution of transplant recipients among the three categories of WT1 mRNA expression levels did not change significantly (data not shown). Table 2 presents the correlation between WT1 mRNA levels and a positive or negative IgH/TCR assay result, both before and after SCT. Clearly, low and intermediate levels of WT1 expression were not related to IgH/TCR rearrangement status prior to SCT. Subsequently, there was an apparent trend toward IgH/TCR negativity in cases with low or intermediate WT1 mRNA levels, but the association was not significant. WT1 mRNA levels before SCT were significantly different neither between IgH/TCR (+) and (À) groups (P ¼ 0.231), nor the CR transplantation and the on disease transplantation groups (P ¼ 0.127) (Figure 1 ). In the 10 cases of Philadelphia chromosome-positive ALL, there was no discernible correlation between positivity for the minor bcr-abl mRNA and IgH/TCR rearrangements (P ¼ 0.30 by Spearman's correlation coefficient; data not shown).
Serial MRD measurements in patients who relapsed
In total, 20 patients had leukemic relapses (14 hematologic and six extramedullary) at a median of 275 days post-SCT (range: 11-665 days). In all, 11 relapses occurred in the 68 CR transplantation group, in contrast to eight out of the 27 on disease transplantation group (P ¼ 0.139). Figure 2 illustrates the relation between the detection of informative IgH/TCR rearrangements and subsequent relapse in the 19 Figure 2 .
Impact of clonal evolution on MRD detection
To explain the failure of MRD detection to predict relapse in the majority of cases, we asked if clonal evolution, or clonal switch, had occurred after detection of the original leukemic clones. As representative cases are illustrated in Figure 3 , 11 of the 14 patients with relapsed ALL showed a totally different PCR rearrangement pattern at the time of leukemic relapse after SCT. Two of the three MRD-positive cases at 6 months (Cases 6, 12, 18; Figure 2 ) were without clonal switch and the remaining case showed the partial conservation of PCR targets (data not shown). To confirm the clonal switch by comparing the sequence of IgH rearrangement at diagnosis and at the time of relapse, materials from six patients were available. Of which only three patients were successfully sequenced, confirming the clonal evolution (Table 3) . MRD was detected 2 weeks earlier than the clinical relapse in Case 6, while in Cases 12 and 18 it was found simultaneously with clinical relapse. In one case with the same clone at diagnosis and relapse (Case 4), MRD was not detected at 3 months post-SCT, with relapse occurring at 7.6 months post-SCT. In the remaining cases, failure to predict relapse was probably because of clonal switches. Findings in Cases 9 and 11 ( Figure 2 ) suggest that clonal evolution can begin as early as 3 months after SCT. The clonal evolution rate was the same between the two risk groups (3/3 in the very high-risk group vs 8/11 in the high-risk group; P ¼ 1.000, by Fisher's exact test). 
Correlation between MRD detection and relapse following SCT
The relation between MRD status at 1 month post-SCT and subsequent relapse was tested in 67 patients. Of the 12 patients who were positive for MRD at this interval, only three relapsed, comparing with 13 of the 55 MRD-negative patients (P ¼ 1.000, Fisher's exact test). Over the first 1-12 months post-SCT, 26 patients had at least one positive MRD result, while 47 were consistently MRD negative.
Relapse rates in these two subgroups were nearly identical (7/26 vs 12/47, P ¼ 1.000 by Fisher's exact test).
Sequential pattern of WT1 mRNA expression after SCT and relapse
We also determined the relation of WT1 mRNA levels at diagnosis to post-SCT leukemic relapse in 74 evaluable patients. There was no difference between relapse rates in patient groups with WT1 mRNA expression levels below or 4 -were recognized in this cohort, but they did not appear to be correlated with the frequency of relapse (Table 4) .
Factors affecting RFS
Six potential risk factors were tested in a univariate Kaplan-Meier analysis of RFS following SCT. These included MRD at 1 month, MRD at 3 months, WT1 mRNA shift patterns, SCT from bone marrow vs cord blood, TBI vs non-TBI conditioning regimens and the presence or absence of active disease at the time of SCT. Only the presence of active disease at transplantation showed a significant adverse impact on this outcome measured up to 24 months of follow-up. The probability of 75% RFS time estimate in the subgroup with active disease (n ¼ 22) was 318 days compared with 665 days for patients without detectable leukemia (n ¼ 52) (P ¼ 0.0445 by the log-rank test; curves not shown). The RFS at 24 months for all 95 patients, and for the 68 patients transplanted in CR was 66.376.3% and 72.577.3%, respectively.
Discussion
The outcome of allogeneic SCT for our 95 pediatric patients with ALL was not directly comparable with previous reports, because the treatment group was heterogeneous and the follow-up period was very short. Compared with a large cohort study with relatively short follow-up of 1 year outcome by Champlin et al 25 21 .1% of relapse rate in our patients were comparable. We tested the impact of MRD on leukemic relapse outcome in these patients. Although 27 of our 95 patients were transplanted on disease, our study interest was to determine if MRD became undetectable post-SCT and it held a prognostic value in these patients. Therefore, we analyzed all 95 patients together, without excluding the patients transplanted on disease. In fact, MRD-negative rate was similar at 1-3 months post-SCT and subsequent relapse rate was not significantly high (P ¼ 0.139) for the on disease transplant group.
Sequential monitoring of MRD has the potential to identify childhood ALL patients at high risk for relapse.
2,4,6-8 However, it remains unclear whether MRD detection after SCT would improve therapeutic decisions regarding transplant recipients. Using multiparameter flow cytometry, Nagler et al 10 analyzed bone marrow specimens both before and 3-4 months after BMT, while the patients were in clinical and morphologic remission. Six of 13 patients (46%) with MRD relapsed, suggesting that MRD detection might provide an effective tool for predicting relapse. Knechtli et al 17, 18 demonstrated that three levels of MRD (high, low and undetectable) at the time of transplantation were significantly correlated with prognosis, and that any evidence of MRD after allogeneic BMT is a poor prognostic sign. Specifically, they assessed MRD at various times up to 24 months post-BMT in 71 children with ALL, and found that 28 of 32 MRD-positive recipients subsequently relapsed. 18 Thus, Goulden et al 5 advocated pretransplant measurements of MRD be included in clinical protocols of BMT for ALL. In the collaborative study reported here, we employed PCR methods similar to those used by Knechtli et al 17, 18 to determine IgH or TCR-d,-g rearrangements followed by electrophoretic size resolution and allele-specific oligonucleotide probing. However, our results were quite different from those of the Knechtli group. That is, 15 of the 19 evaluable patients who relapsed had a negative MRD test 1-12 months earlier (Figure 2 ), most likely because the high rate of clonal evolution prevented accurate detection of MRD with predetermined sets of primers. [26] [27] [28] [29] In a study of 96 children with relapsed B-precursor ALL, Szczepanski et al 30 found that PCR targets identified at diagnosis were lost entirely in 10 patients and preserved in 36, while portions of the targets were absent in samples from 38 patients. In the present study, a loss of PCR targets was demonstrated in 11 of 14 cases of post-SCT relapse. Thus, we conclude that MRD detection post-SCT, using the above procedures, can be problematic. To overcome this problem, it was reported that in the case of PCR analysis of IgH/TCR gene rearrangements, four sets of primers appear capable of detecting at least one clone-specific rearrangement in more than 90% of patients. 5 Accordingly, the standardized techniques for IgH/TCR rearrangements and TAL1 deletions as PCR targets were proposed in the detection of MRD in ALL. 31 More recently, Szczepanski et al 32 demonstrated that 71% of clonal Ig and TCR targets were preserved at relapse with use of complex methods of stepwise targets' selection for MRD-PCR detection in childhood precursor-B ALL. However, the relatively short interval from MRD detection to clinical relapse in post-SCT ALL raises serious questions about the practicality of these meticulous procedures.
It was surprising that the WT1 mRNA expression levels neither correlated well with MRD detection by IgH/TCR assays nor predicted clinical leukemic relapse in our study. According to Sugiyama and co-workers, [19] [20] [21] Although our data represent one of the largest populations of allogeneic SCT patients reported to date in pediatric ALL, the study cohort was very heterogeneous: different disease status at the time of study, use of different source of stem cells, use of different conditioning regimens, etc. Sample sizes at some time points and in some categories of MRD were small. Moreover, there may have been an excessive number of false-negative results because of crude division of cases into MRD-positive or MRD-negative groups. However, the most striking was the lack of correlation between the levels of WT1 expression and those of IgH/TCR rearrangement, partly because of low specificity of WT1 expression and high rate of 'clonal switch' in pediatric ALL during the post-transplant course. Based on the results, although there were some limitations, we conclude that sequential MRD monitoring with IgH/TCR or WT1 mRNA assays is not likely to have a significant impact on clinical management decisions following SCT in children with ALL, even if the loss of critical PCR targets could be averted.
